about
Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemiaDeletion of the RNA-binding proteins ZFP36L1 and ZFP36L2 leads to perturbed thymic development and T lymphoblastic leukemiaHigh accuracy mutation detection in leukemia on a selected panel of cancer genesDeletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia.The TLX1 oncogene drives aneuploidy in T cell transformationRibosomopathies and the paradox of cellular hypo- to hyperproliferation.Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemiaGenetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia.Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL.Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia.Chronic myeloproliferative disorders: a tyrosine kinase tale.Bypass of the pre-60S ribosomal quality control as a pathway to oncogenesis.The ribosomal protein gene RPL5 is a haploinsufficient tumor suppressor in multiple cancer types.The genetics and molecular biology of T-ALL.NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins.RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response.Targeting nonclassical oncogenes for therapy in T-ALL.Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia.Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia.Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia.In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia.Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia.Low frequency mutations in ribosomal proteins RPL10 and RPL5 in multiple myeloma.The other Achilles' heel of BCR-ABL1.JAK1 mutation analysis in T-cell acute lymphoblastic leukemia cell lines.T-ALL: ALL a matter of Translation?Novel insights on TLX1 function in T-ALL pave the way towards differentiation therapy.A novel mouse model provides insights into the neutropenia associated with the ribosomopathy Shwachman-Diamond syndrome.Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases.Ribosomal proteins: a novel class of oncogenic drivers.How Ribosomes Translate Cancer.The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling.T-Cell acute lymphoblastic leukemia with a "pinch" of BCR-ABL1.TLX1-induced T-cell acute lymphoblastic leukemia.Ribosomal RNA analysis in the diagnosis of Diamond-Blackfan Anaemia.Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia.VEGFC Antibody Therapy Drives Differentiation of AMLCancer Biogenesis in Ribosomopathies
P50
Q24596097-5B99905C-85D1-4511-A596-F61C07787829Q24632890-98441171-74BD-4AEB-974C-637593C53F36Q28728910-AF4ADAFC-F741-4198-A61D-1038DE7EC087Q34213990-F61D55AE-9E4B-4944-B2F1-16456B07E37AQ34283329-5310FDF6-A747-456B-8793-231CFF5F4B18Q34457472-43475A61-DBC0-4B06-A23B-C463AFD741F9Q35075158-52F1684A-180E-487D-8AAF-9AA5F6482400Q35742745-07B8551F-A380-4A87-895F-11EE58C0D8F6Q35816648-E7EC6832-4D11-45D4-BD5A-5E8E8C5E1AB7Q36217949-92D3D04F-8FE5-4D7D-AD7E-30349E2686F9Q36337918-21D783DA-D540-4EA5-9808-480B90BDD5E4Q37711977-1715C451-30BD-40B8-8F40-EB4D4AEA0A51Q38986278-48E58D1F-E95D-4468-BDAA-6ADB944E0EC8Q39099555-29831D18-5F5B-4DD4-8E43-E3682AA87907Q39122858-61FEC784-EFF4-4CA9-A219-67E7FDF53047Q39137868-B3AB58DF-DB82-4309-84F4-E080437BE8ADQ39362097-3C4CA403-6823-4549-9DAE-AC9F26FFB994Q39375742-37BF7AB7-C39C-4C08-88D5-E69A47E6E09DQ39526312-A2E53E4D-6022-47E4-8714-90E023E5AD3FQ39928804-B93E070F-49FD-4A1E-A3FB-5943248F4224Q40005395-FBFD1B16-552A-40B9-8058-664D41C6DAEFQ40145557-E50774A6-64CD-4FA1-96F5-414AD3C8344FQ40457799-896B2B4F-4E71-4324-B067-AD50DABBA95CQ41296537-765F9653-1C49-4540-BFC4-373B908BC45DQ42341708-EA748055-0A5C-4844-8C9A-05378FC26647Q43043023-2639D818-DE8D-48AA-B87A-CE182CAFF402Q43171550-1938B9E0-94EE-4CFE-A240-82501112AEDEQ43175143-C9F239B7-6D6A-4F66-B51C-4081558413FDQ43188721-3BC3B4E8-A0FE-4102-99A6-DC4FAD66AF56Q43234238-64142564-3C10-410B-821F-3FBEE83B4B56Q46375245-BCB7BE31-D13E-4911-AE14-CA2D6952A3EBQ46706297-F596737F-6439-4A5A-9BE7-3DAC6C9C8B30Q47782255-E7630A74-56BA-43B6-9FAE-F1402587A8EDQ48027760-F67C0635-0BCE-42DF-B43A-EEC1CF56DDF0Q51763568-03EA11E6-F131-4187-B718-71344F115993Q51863047-3901C101-5CB1-4469-8D14-6C5D8DA5FD1EQ52889198-FCEF3EC3-7FE1-4914-BAAB-593D2B83FD25Q54963328-BB9CCD69-8D87-48F9-8D50-4AA35F7E92D8Q57461983-BAF05303-4429-4C9B-A4AA-F99863862293Q64106716-C96DDDE3-91E1-4055-A1FA-3FE9D41518F1
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Kim De Keersmaecker
@ast
Kim De Keersmaecker
@en
Kim De Keersmaecker
@es
Kim De Keersmaecker
@nl
Kim De Keersmaecker
@sl
type
label
Kim De Keersmaecker
@ast
Kim De Keersmaecker
@en
Kim De Keersmaecker
@es
Kim De Keersmaecker
@nl
Kim De Keersmaecker
@sl
prefLabel
Kim De Keersmaecker
@ast
Kim De Keersmaecker
@en
Kim De Keersmaecker
@es
Kim De Keersmaecker
@nl
Kim De Keersmaecker
@sl
P106
P1153
24070397400
P31
P496
0000-0002-7420-9531